Navigation Links
Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
Date:12/7/2007

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Society of Hematology Meeting, December 8 - 11 in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The session will open at 10:30 a.m. and poster presentations will be held from 5:00 to 7:00 p.m. for each abstract. Additional information can be accessed through the links provided below.

-- Poster # 897-III: "High Incidence of Progression to Chronic Renal

Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria

(PNH)" Dr. Peter Hillmen et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416

-- Poster # 891-III: "Sustained Improvements in Transfusion

Requirements, Fatigue and Thrombosis with Eculizumab Treatment in

Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204

-- Poster # 902-III: "Disease-Related Symptoms Reported across a Broad

Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr.

Gabrielle Meyers et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438.

The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.

-- Publication Number 840: "Significant Disease Burden in Paroxysmal

Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis,

Mild Anemia and Minimal Transfusion: Clinical Improvement with

Eculizumab Therapy" Dr. Monica Bessler et al.

-- Location: Rooms B213-B214

-- Tuesday, December 11, 2007 - 8:45 a.m.

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302.


'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Alexion Pharmaceuticals Invites You to Participate in its Third Quarter 2007 Results Conference Call and Web Cast
2. Alexion to Present at Investor Conferences
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 2017 , ... According to the American Society of Plastic Surgeons (ASPS), over ... top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, it’s ... the next 8-10 weeks. For anyone considering a hair removal procedure, there are a ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, ... conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue ... ET. This conference discusses strategies to prevent readmissions in light of the most ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans ... been used for thousands of years. , "The West has caught on, and has ... How to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
(Date:3/29/2017)... Indianapolis, IN (PRWEB) , ... March 29, 2017 ... ... Benefits Study, this webinar provides insight into the challenges employers face in trying ... the complexity of managing employee benefits programs? Adding to the growing complexity, ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... , March 30, 2017  Akcea Therapeutics, a subsidiary ... initiation of a Phase 2b dose-ranging study of AKCEA-APO(a)-L ... disease. The goal of the study is to determine ... Rx in a planned Phase 3 cardiovascular outcome ... of Akcea,s strategic collaboration with Novartis to develop and ...
(Date:3/30/2017)... DUBLIN , Mar 30, 2017 ... "Hemodialysis And Peritoneal Dialysis Market Size & Forecast, By Type ... (Home-based, Hospital-based), And Trend Analysis From 2014 To 2025" ... ... market is expected to reach USD 108.5 billion by 2025. ...
(Date:3/29/2017)... Research and Markets has announced the ... Forecast By Type (Insource IONM, Outsource IONM), By Region And ... offering. ... The global Intraoperative Neuromonitoring (IONM) market is expected to ... is anticipated to witness significant growth in the forecast period, ...
Breaking Medicine Technology: